← Leaderboards
Charbel Moussa
Georgetown University
$7,027,361
Attributed
$7,027,361
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2008–22$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$7,027,361 · 2
By mechanism
R01$6,420,124 · 1
K01$607,237 · 1
Top collaborators
No co-investigators on record.
Most similar at Georgetown University
Same institution · by research overlap
- Anita Sidhu$9,380,408
- Martin Morad$8,734,154
- Stefano Vicini$8,803,601
- Christopher S Wilcox$17,361,029
- Dan Wang$1,307,658
Others in their field
Top investigators on “S Disease”
- Lawrence Corey · Fred Hutchinson Cancer Center$643,566,627
- Jeffrey P Krischer · University Of South Florida$588,279,843
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$477,614,997
- David Heimbrook · Leidos Biomedical Research, Inc.$470,438,912
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$389,132,404
Research focus
S DiseaseNeurodegenerative DisordersProteinsTau ProteinsDementiaAlzheimer&AposNerve DegenerationPathologyAnimal ModelBrainParkinson DiseaseAlpha SynucleinAttenuationAttenuatedAntineoplastic AgentsAgreementActivities Of Daily LivingCellsAmyloid ProteinsBiological MarkersBehavioral SymptomsBrain ChemistryAffectAcids
Grant awards (10)
A randomized, double blind, placebo-controlled study to evaluate the impact of Nilotinib treatment on safety, tolerability, pharmacokinetics and biomarkers in Dementia with Lewy Bodies (DLB)$1,417,321
R01 · FY2022 · AG · contact PI
A randomized, double blind, placebo-controlled study to evaluate the impact of Nilotinib treatment on safety, tolerability, pharmacokinetics and biomarkers in Dementia with Lewy Bodies (DLB)$1,792,741
R01 · FY2021 · AG · contact PI
A randomized, double blind, placebo-controlled study to evaluate the impact of Nilotinib treatment on safety, tolerability, pharmacokinetics and biomarkers in Dementia with Lewy Bodies (DLB)$1,417,321
R01 · FY2020 · AG · contact PI
A randomized, double blind, placebo-controlled study to evaluate the impact of Nilotinib treatment on safety, tolerability, pharmacokinetics and biomarkers in Dementia with Lewy Bodies (DLB)$375,420
R01 · FY2020 · AG · contact PI
A randomized, double blind, placebo-controlled study to evaluate the impact of Nilotinib treatment on safety, tolerability, pharmacokinetics and biomarkers in Dementia with Lewy Bodies (DLB)$1,417,321
R01 · FY2019 · AG · contact PI
Parkin protection in gene transfer animal models (KO-1 Award)$127,094
K01 · FY2012 · AG · contact PI
Parkin protection in gene transfer animal models (KO-1 Award)$127,094
K01 · FY2011 · AG · contact PI
Parkin protection in gene transfer animal models (KO-1 Award)$122,407
K01 · FY2010 · AG · contact PI
Parkin protection in gene transfer animal models (KO-1 Award)$117,607
K01 · FY2009 · AG · contact PI
Parkin protection in gene transfer animal models (KO-1 Award)$113,035
K01 · FY2008 · AG · contact PI